Latigo Biotherapeutics, Inc.
LTGODrugs in Pipeline
3
Phase 3 Programs
0
Upcoming Catalysts
1
Next Catalyst
Dec 2026
Market Overview
Stock performance and key metrics
Get an email about LTGO's next catalysts
Track Latigo Biotherapeutics (LTGO) and we email you when an FDA date moves, 7 days and 1 day before the decision when the exact day is known, and when it is announced. Free account, no card.
1 upcoming, 0 past
LTGO Earnings Report
Date estimated from past reporting pattern, not yet confirmed by the company | FQ end Sep/2026 | Call: tbd
LTG-001 High Dose
Acute Pain, Postoperative
LTG-001 Low Dose
Acute Pain
LTG-001 Mid Dose
Acute Pain, Postoperative
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
LTG-001 High Dose | Phase 2 | Acute Pain, Postoperative | - | - |
LTG-001 Low Dose | Phase 2 | Acute Pain | - | - |
LTG-001 Mid Dose | Phase 2 | Acute Pain, Postoperative | - | - |
Source: CatalystAlert database (ClinicalTrials.gov, SEC EDGAR)
Full breakdown — the signals behind the verdict
Frequently asked questions
What is in Latigo Biotherapeutics, Inc.'s drug pipeline?→
CatalystAlert tracks 3 drug candidates in Latigo Biotherapeutics, Inc.'s (LTGO) pipeline across Phase 2. Its lead program is LTG-001 High Dose (Phase 2). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is Latigo Biotherapeutics, Inc.'s next FDA catalyst?→
CatalystAlert tracks every upcoming catalyst for Latigo Biotherapeutics, Inc. (LTGO) — PDUFA decision dates, Phase 1/2/3 trial readouts, FDA advisory committee meetings and NDA/BLA filings — each confidence-rated as confirmed, estimated or AI-detected.
How do I track LTGO biotech catalysts?→
Add LTGO to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow Latigo Biotherapeutics, Inc.'s live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.